Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Trsar v. Akorn, Inc. et al
Case Number:
1:18-cv-07374
Court:
Nature of Suit:
Multi Party Litigation:
Class Action, Derivative Litigation
Judge:
Firms
Companies
Sectors & Industries:
-
February 15, 2019
Investor Reaffirms Suit Accusing Akorn Execs Of Deceit
An Akorn Inc. investor told an Illinois federal court the pharmaceutical company's executives should not be able to dodge a suit alleging they lied in public statements for their own benefit, concealed regulatory problems and sunk a major merger deal with their inept behavior.
-
January 15, 2019
Akorn Wants Derivative Suit Related To Failed Merger Axed
Akorn Inc. told an Illinois federal judge on Monday that a shareholder's consolidated derivative suit claiming the pharmaceutical company's falsified regulatory submissions sunk a multibillion-dollar merger and tanked Akorn's share price doesn't offer allegations to support a securities claim and must be tossed.
-
November 07, 2018
Investors Sue Akorn After Failed Merger 'Debacle' Kills Stock
An Akorn Inc. shareholder sued the pharmaceutical company's executives and board members on Tuesday in Illinois federal court over falsified submissions to the U.S. Food and Drug Administration, a "debacle" that sunk a multibillion-dollar merger and plunged Akorn's share price by nearly 50 percent.